Heartio has just secured a seed financing that will enable it to commercialize non-invasive, AI-driven cardiac diagnostics. Their product ECGio is an AI-enabled digital diagnostic tool designed to detect coronary artery disease and predict coronary occlusion. Unlike traditional invasive methods, it uses deep learning to analyze a standard 12-lead electrocardiogram (ECG) to provide faster, more accurate and lower cost results.

The technology’s efficacy has been supported by 2 major publications. In its paper on the Canadian Journal of Cardiology, Heartio has demonstrated the technology’s ability to predict coronary artery disease in stable patients, using only a standard ECG. In it’s publication in the JACC Advances, the technology was validated by a study on over 16000 patients.

The funding will be used to launch a pivotal study required for FDA clearance of their flagship AI platform.

The company’s ultimate goal is to democratize cardiovascular care. By making early detection scalable and affordable, Heartio seeks to shift the standard of care toward a future where heart attacks are preventable through early non-invasive methods.